Pharma facility news in brief
pharmafile | November 4, 2013 | News story | Manufacturing and Production |Â Â DSM, GSK, manufacturingÂ
Carbogen Amcis has upgraded its production units for high-potency active pharmaceutical ingredients (HPAPIs) at Bubendorf, Switzerland, and Bavla in India.
The niche-scale plant in Bubendorf gains a 55 sq. m. dedicated chromatography suite for small-volume purification of Category 3 and 4 compounds.
Meanwhile, at the commercial-scale plant in Bavla the company has installed a 110 sq. m. class 100,000 high-potency kilo lab. The latest rounds of investment come shortly after Carbogen Amcis started upgrading its antibody-drug conjugate plants in Bubendorf and Riom in France.
DSM Pharmaceutical Products has opened a mammalian cell culture facility for GMP biopharmaceutical contract manufacturing in Brisbane, Australia, that was set up in partnership with trade group Biopharmaceuticals Australia. The plant has been designed with flexibility in mind and makes extensive use of disposable equipment and will be able to support projects from pre-clinical through Phase III and commercial-scale production.
The first customers have already been signed up for the new facility and include DecImmune Therapeutics of the US, Brazil’s Recepta Biopharma, and Australian companies Paranta Biosciences and Opthea.
Cambrex has opened an expanded facility for the production of Dow’s recently-launched Affinisol (hypromellose acetate succinate; HPMCAS) excipient – a water-soluble polymer used to enhance drug solubility in spray-dried dispersion formulations – at its Karlskoga site in Sweden.
The expansion got under way earlier this year to support a drug solubilisation partnership between Dow and Bend Research – recently acquired by Capsugel – that was unveiled in October 2012. Excipients made at the plant will be ready for sales in early 2014, said Dow in a statement.
GlaxoSmithKline (GSK) has set up a partnership with the São Paulo Research Foundation (FAPESP) in Brazil that will set up a new centre dedicated to sustainable chemistry, including finding more environmentally-friendly ways to manufacture medicinal products. FAPESP and GSK have both agreed to invest £400,000 ($637,000) per year in the centre over 10 years.
GSK already supports a similar green chemistry centre at the University of Nottingham in the UK which is in the process of being set up. The two units will share expertise on projects such as improving synthetic efficiency, developing sustainable solvents and using renewable feed-stocks from agricultural waste.
US company TriLink BioTechnologies has said it plans to build a 2,000 sq. ft. pharmaceutical GMP production suite within its facility in San Diego. The manufacturing facility will span nine laboratories and will be equipped to manufacture and process mRNA, long RNA, aptamers, oligonucleotides, small molecules and nucleoside triphosphates, used in research and diagnostic markets. The build is scheduled to complete in the first quarter of 2014.
Phil Taylor
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
